The skin functions as more than a physical barrier to infection. Epithelial cells of the skin can synthesize antimicrobial peptides, including defensins, which exhibit direct antimicrobial activity. Here we characterize the expression pattern, genetic variation and activity of the major β-defensin expressed in canine skin, canine β-defensin 103 (CBD103). The gene encoding CBD103 exhibits two forms of polymorphism: a common 3-basepair deletion allele and a gene copy-number variation. Golden retrievers and Labrador retrievers were the only breeds that encoded the variant allele of CBD103, termed CBD103 ΔG23. Both these breeds also exhibited a CBD103 gene copy-number polymorphism that ranged from 2 to 4 gene-copies per diploid genome. Recombinant CBD103 and CBD103ΔG23, as well as the human ortholog human β-defensin 3 (hBD3) and hBD3ΔG23, showed potent and comparable antimicrobial killing against both methicillin-susceptible and methicillin-resistant Staphylococcus pseudintermedius. Skin biopsy specimens from dogs with atopic dermatitis revealed CBD103 expression levels similar to those in healthy controls and comparable at lesional and nonlesional sites. This expression pattern in dogs differs from the previously reported reduced expression of the human ortholog in atopic dermatitis. Overall, the similarities of CBD103 and its human ortholog reported here support the notion that the domestic dog may serve as a valuable model for studying β-defensin biology in the skin.

Keywords:
Canine beta-defensin, Skin, Antimicrobial peptides, Epidermis, Atopic dermatitis
1.
Schroder JM, Harder J: Antimicrobial skin peptides and proteins. Cell Mol Life Sci 2006;63:469–486.
2.
Bernard JJ, Gallo RL: Protecting the boundary: the sentinel role of host defense peptides in the skin. Cell Mol Life Sci 2011;68:2189–2199.
3.
Ganz T: Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003;3:710–720.
4.
Ganz T: Defensins: antimicrobial peptides of vertebrates. C R Biol 2004;327:539–549.
5.
Lehrer RI: Primate defensins. Nat Rev Microbiol 2004;2:727–738.
6.
Varoga D, Pufe T, Harder J, Schroder JM, Mentlein R, Meyer-Hoffert U, Goldring MB, Tillmann B, Hassenpflug J, Paulsen F: Human beta-defensin 3 mediates tissue remodeling processes in articular cartilage by increasing levels of metalloproteinases and reducing levels of their endogenous inhibitors. Arthritis Rheum 2005;52:1736–1745.
7.
Bowdish DM, Davidson DJ, Hancock RE: Immunomodulatory properties of defensins and cathelicidins. Curr Top Microbiol Immunol 2006;306:27–66.
8.
Candille SI, Kaelin CB, Cattanach BM, Yu B, Thompson DA, Nix MA, Kerns JA, Schmutz SM, Millhauser GL, Barsh GS: A β-defensin mutation causes black coat color in domestic dogs. Science 2007;318:1418–1423.
9.
Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151–1160.
10.
Howell MD, Boguniewicz M, Pastore S, Novak N, Bieber T, Girolomoni G, Leung DY: Mechanism of hBD-3 deficiency in atopic dermatitis. Clin Immunol 2006;121:332–338.
11.
Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk-Olthuis D, van de Kerkhof PC, Traupe H, de Jongh G, den Heijer M, Reis A, Armour JA, Schalkwijk J: Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008;40:23–25.
12.
Meyer-Hoffert U, Schwarz T, Schroder JM, Glaser R: Expression of human beta-defensin-2 and -3 in verrucae vulgares and condylomata acuminata. J Eur Acad Dermatol Venereol 2008;22:1050–1054.
13.
Meyer-Hoffert U, Schwarz T, Schroder JM, Glaser R: Increased expression of human beta-defensin 3 in mollusca contagiosum. Clin Exp Dermatol 2010;35:190–192.
14.
Patil AA, Cai Y, Sang Y, Blecha F, Zhang G: Cross-species analysis of the mammalian β-defensin gene family: presence of syntenic gene clusters and preferential expression in the male reproductive tract. Physiol Genomics 2005;23:5–17.
15.
Wingate KV, Torres SM, Silverstein KA, Hendrickson JA, Rutherford MS: Expression of endogenous antimicrobial peptides in normal canine skin. Vet Dermatol 2009;20:19–26.
16.
Erles K, Brownlie J: Expression of beta-defensins in the canine respiratory tract and antimicrobial activity against bordetella bronchiseptica. Vet Immunol Immunopathol 2010;135:12–19.
17.
Harder J, Bartels J, Christophers E, Schroder JM: A peptide antibiotic from human skin. Nature 1997;387:861.
18.
Harder J, Bartels J, Christophers E, Schroder JM: Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001;276:5707–5713.
19.
Chen WK, Swartz JD, Rush LJ, Alvarez CE: Mapping DNA structural variation in dogs. Genome Res 2009;19:500–509.
20.
Hardwick RJ, Machado LR, Zuccherato LW, Antolinos S, Xue Y, Shawa N, Gilman RH, Cabrera L, Berg DE, Tyler-Smith C, Kelly P, Tarazona-Santos E, Hollox EJ: A worldwide analysis of beta-defensin copy number variation suggests recent selection of a high-expressing DEFB103 gene copy in East Asia. Hum Mutat 2011;32:743–750.
21.
Marsella R, Girolomoni G: Canine models of atopic dermatitis: a useful tool with untapped potential. J Invest Dermatol 2009;129:2351–2357.
22.
Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, Darst MA, Gao B, Boguniewicz M, Travers JB, Leung DY: Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003;171:3262–3269.
23.
Kisich KO, Carspecken CW, Fieve S, Boguniewicz M, Leung DY: Defective killing of Staphylococcus aureus in atopic dermatitis is associated with reduced mobilization of human beta-defensin-3. J Allergy Clin Immunol 2008;122:62–68.
24.
van Damme CM, Willemse T, van Dijk A, Haagsman HP, Veldhuizen EJ: Altered cutaneous expression of beta-defensins in dogs with atopic dermatitis. Mol Immunol 2009;46:2449–2455.
25.
Wehkamp J, Chu H, Shen B, Feathers RW, Kays RJ, Lee SK, Bevins CL: Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues. FEBS Letters 2006;580:5344–5350.
26.
Leonard BC, Chu H, Johns JL, Gallo RL, Moore PF, Marks SL, Bevins CL: Expression and activity of a novel cathelicidin from domestic cats. PLoS One 2011;6:e18756.
27.
Brinkhof B, Spee B, Rothuizen J, Penning LC: Development and evaluation of canine reference genes for accurate quantification of gene expression. Anal Biochem 2006;356:36–43.
28.
Toonen RJ, Hughes S: Increased throughput for fragment analysis on an ABI prism 377 automated sequencer using a membrane comb and STRand software. Biotechniques 2001;31:1320–1324.
29.
Linzmeier RM, Ganz T: Human defensin gene copy number polymorphisms: comprehensive analysis of independent variation in alpha- and beta-defensin regions at 8p22-p23. Genomics 2005;86:423–430.
30.
Lehrer RI, Rosenman M, Harwig SS, Jackson R, Eisenhauer P: Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods 1991;137:167–173.
31.
Merryman-Simpson AE, Wood SH, Fretwell N, Jones PG, McLaren WM, McEwan NA, Clements DN, Carter SD, Ollier WE, Nuttall T: Gene (mRNA) expression in canine atopic dermatitis: microarray analysis. Vet Dermatol 2008;19:59–66.
32.
Harder J, Schroder JM: Antimicrobial peptides in human skin. Chem Immunol Allergy 2005;86:22–41.
33.
Harder J, Meyer-Hoffert U, Wehkamp K, Schwichtenberg L, Schroder JM: Differential gene induction of human beta-defensins (hBD-1, -2, -3, and -4) in keratinocytes is inhibited by retinoic acid. J Invest Dermatol 2004;123:522–529.
34.
Sorensen OE, Cowland JB, Theilgaard-Monch K, Liu L, Ganz T, Borregaard N: Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J Immunol 2003;170:5583–5589.
35.
Sorensen OE, Thapa DR, Rosenthal A, Liu L, Roberts AA, Ganz T: Differential regulation of beta-defensin expression in human skin by microbial stimuli. J Immunol 2005;174:4870–4879.
36.
Kisich KO, Howell MD, Boguniewicz M, Heizer HR, Watson NU, Leung DY: The constitutive capacity of human keratinocytes to kill Staphylococcus aureus is dependent on beta-defensin 3. J Invest Dermatol 2007;127:2368–2380.
37.
Fazakerley J, Crossley J, McEwan N, Carter S, Nuttall T: In vitro antimicrobial efficacy of beta-defensin 3 against Staphylococcus pseudintermedius isolates from healthy and atopic canine skin. Vet Dermatol 2010;21:463–468.
38.
Santoro D, Bunick D, Graves TK, Campbell KL: Expression and distribution of antimicrobial peptides in the skin of healthy beagles. Vet Dermatol 2011;22:61–67.
39.
Everts RE, Rothuizen J, van Oost BA: Identification of a premature stop codon in the melanocyte-stimulating hormone receptor gene (Mc1r) in Labrador and Golden retrievers with yellow coat color. Anim Genet 2000;31:194–199.
40.
Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, Bevins CL, Reinisch W, Teml A, Schwab M, Lichter P, Radlwimmer B, Stange EF: A chromosome 8 gene cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn’s disease of the colon. Am J Hum Genet 2006;79:439–448.
41.
Groth M, Wiegand C, Szafranski K, Huse K, Kramer M, Rosenstiel P, Schreiber S, Norgauer J, Platzer M: Both copy number and sequence variations affect expression of human DEFB4. Genes Immun 2010;11:458–466.
42.
Boguniewicz M, Leung DY: Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011;242:233–246.
43.
DeBoer DJ, Marsella R: The ACVD task force on canine atopic dermatitis (XII): the relationship of cutaneous infections to the pathogenesis and clinical course of canine atopic dermatitis. Vet Immunol Immunopathol 2001;81:239–249.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.